Targeted radiation shows promise for Hard-to-Treat blood cancers
NCT ID NCT02952508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cells. The study has two parts: one looks at how many patients benefit across several cancer types, and the other focuses on Waldenstrom macroglobulinemia. About 120 adults aged 18 and older are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cellectar Biosciences
Atlanta, Georgia, 30332, United States
-
Cellectar Biosciences
Bethesda, Maryland, 20817, United States
-
Cellectar Biosciences
North Bergen, New Jersey, 07047, United States
-
Cellectar Biosciences
Canton, Ohio, 44718, United States
-
Cellectar Biosciences
Greenville, South Carolina, 29605, United States
-
Cellectar Biosciences
Adelaide, South Australia, 5000, Australia
-
Cellectar Biosciences
Salvador, Estado de Bahia, 40050-410, Brazil
-
Cellectar Biosciences
Curitiba, Paraná, 80810-050, Brazil
-
Cellectar Biosciences
Porto Alegre, RioGrande Do Sul, 90035-903, Brazil
-
Cellectar Biosciences
Blumenau, Santa Catarina, 89010-340, Brazil
-
Cellectar Biosciences
Helsinki, 00029, Finland
-
Cellectar Biosciences
Pessac, 33600, France
-
Cellectar Biosciences
Poitiers, 86021, France
-
Cellectar Biosciences
Barcelona, 08036, Spain
-
Cellectar Biosciences
Madrid, 28027, Spain
-
Cellectar Biosciences
Madrid, 28040, Spain
-
Cellectar Biosciences
Salamanca, 37007, Spain
-
Cellectar Biosciences
Ankara, 06620, Turkey (Türkiye)
-
Cellectar Biosciences
Bornova, 35100, Turkey (Türkiye)
-
Cellectar Biosciences
Istanbul, 34093, Turkey (Türkiye)
-
Cellectar Biosciences Site
Charleston, South Carolina, 29425, United States
-
Cellectar Biosciences Site
Hradec Králové, 500 05, Czechia
-
Cellectar Biosciences Site
Rio, Greece
-
Cellectar Biosciences Site
Jerusalem, Israel
-
Cellectar Biosciences site
Los Angeles, California, 90095, United States
-
Cellectar Biosciences site
Redlands, California, 92373, United States
-
Cellectar Biosciences site
Washington D.C., District of Columbia, 20007, United States
-
Cellectar Biosciences site
Jacksonville, Florida, 32224, United States
-
Cellectar Biosciences site
Miami, Florida, 33165, United States
-
Cellectar Biosciences site
Tampa, Florida, 33612, United States
-
Cellectar Biosciences site
Maywood, Illinois, 60153, United States
-
Cellectar Biosciences site
Warrenville, Illinois, 60555, United States
-
Cellectar Biosciences site
Westwood, Kansas, 66205, United States
-
Cellectar Biosciences site
New Orleans, Louisiana, 70121, United States
-
Cellectar Biosciences site
Baltimore, Maryland, 21287, United States
-
Cellectar Biosciences site
Boston, Massachusetts, 02215, United States
-
Cellectar Biosciences site
Buffalo, New York, 14263, United States
-
Cellectar Biosciences site
New York, New York, 10065, United States
-
Cellectar Biosciences site
Rochester, New York, 14642, United States
-
Cellectar Biosciences site
Durham, North Carolina, 27705, United States
-
Cellectar Biosciences site
Cincinnati, Ohio, 45219, United States
-
Cellectar Biosciences site
Knoxville, Tennessee, 37920, United States
-
Cellectar Biosciences site
Dallas, Texas, 75246, United States
-
Cellectar Biosciences site
Dallas, Texas, 75390, United States
-
Cellectar Biosciences site
Houston, Texas, 77030, United States
-
Cellectar Biosciences site
Seattle, Washington, 98109, United States
-
Cellectar Biosciences site
Madison, Wisconsin, 53792, United States
-
Cellectar Biosciences site
Concord, New South Wales, 2139, Australia
-
Cellectar Biosciences site
Athens, 115 28, Greece
-
Cellectar Biosciences site
Barcelona, 08908, Spain
-
Cellectar Biosciences site
Zaragoza, 50009, Spain
-
Cellectar Biosciences site
London, NW1 2PG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can an immune booster outsmart brain lymphoma?
- Can lifestyle choices after a stroke extend life and prevent a second one?